Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
Clinical trial NCT01634763 · COMPLETED
Trial details
- NCT number
- NCT01634763
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-06-01
- Primary completion
- 2016-01-01
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.